Navamedic ASA (DE:N1A) has released an update.
Navamedic ASA has announced a partnership with digital health provider Alex Therapeutics to launch a Parkinson’s treatment management app. The app, designed to support patients using Navamedic’s Flexilev®, offers personalized medication management and complements their dose dispenser OraFID®. Set for release in the Nordic countries with plans for global expansion, this initiative aims to improve the quality of life for those living with Parkinson’s disease.
For further insights into DE:N1A stock, check out TipRanks’ Stock Analysis page.